Introduction
Prostate cancer (PCa) is now recognized as one of the principal medical problems facing the male population. In the United States, PCa accounts for the largest percentage of new male cancer cases and is the second leading cause of cancer death in men. In 2012, there will be an estimated 241,740 new cases and 28,170 deaths from PCa in America (Siegel et al., 2012) .
The use of prostate-specific antigen (PSA) as a screening tool has revolutionized the detection of earlystage PCa (Schmid et al., 2004) . Since PSA testing has become popular for diagnosis in China, the incidence of PCa is also increasing rapidly, especially in more developed cities (Li et al., 2009) .
However, PSA though highly sensitive, it is organspecific and not cancer-specific, which results in difficulties in discriminating malignant and benign prostatic status (e.g., benign prostatic hyperplasia and prostatitis) in men with slight elevations of PSA. There have been several reports on clinical variables, which may improve the specificity in the early detection of PCa, including PSA density (PSAD), PSA dynamics (velocity and doubling time) and PSA molecular forms as adjuncts to total serum PSA measurements (De Visschere et al., 2010) . Some guidelines do incorporate PSA velocity (PSAV) cut points as an indicator for biopsy (Vickers et al., 2009) .The utility of PSAV in PCa screening is controversial (Etzioni et al., 2007) . Carter et al. and others have shown that PSAV may improve cancer detection (Carter et al., 1992; Vickers et al., 2009) , whereas others have been unable to demonstrate an incremental value beyond total PSA alone (Schroder et al., 2006; Thompson et al., 2006) . Recently, PSAV per initial volume (PSAVD) has been proposed by Choi et al. as a new indicator for PCa detection (Choi et al., 2011) .
The incidence rate of PCa per 100,000 is 152.9 in the United States, but only 11.8 in China (Li et al., 2009; Siegel et al., 2012) . Chinese men are expected to have substantially lower prostate volumes than Caucasian men (Chang et al., 2006; Xie et al., 2007) . It is thus not clear whether the established PCa early detection guidelines from Europe and USA, are also applicable to Chinese. In the present study we evaluated the utility of PSAV and PSAVD for early detection of PCa in Chinese men.
Materials and Methods

Patients
Between January 2009 and June 2012, a total of 1786 patients underwent prostate biopsy by transrectal ultrasonography (TRUS) based on a cancer-detection program at our hospital, in which men with serum PSA levels of ≥4.0ng/mL or abnormal DRE findings were recommended for biopsy. Both asymptomatic men who were referred for PCa screening because of elevated PSA levels, and those symptomatic with benign prostatic hyperplasia (BPH) were included. 193 men had received at least 2 concurrent serum PSA measurements, along with 2 prostate volume (PV) measurements by TRUS before they underwent prostate biopsy. Clinical characteristics of the patients are summarized in Table 1 . The study was approved by the institutional review board and written informed consent was obtained from each patient before enrollment. Patients were excluded from analysis if they had received any medication that might influence serum PSA levels, or if they had a history of prostatic surgery.
Parameters and prostate biopsy
Serum PSA level was determined beforehand using the EIA method. Ultrasonographic images of the prostate were obtained by TRUS using a commercially available device. The volume of the whole prostate was calculated using the ellipsoid volume formula (Terris et al., 1991) .This formula is defined by measuring the height(H), width(W), and length(L) of the prostate from two selected orthogonal views and calculating the PV as that of the corresponding ellipsoid: PV=π/6×W×H×L (Xie et al., 2007) .
PSAV, PSAD and PSAVD were defined as [PSAV= (serum PSA level of last visit -serum PSA level of initial visit)/follow-up years] (McLaren et al., 1998), [PSAD=last serum PSA level/last PV] (Bretton et al., 1994) , [PSAVD = PSAV /initial PV] (Choi et al., 2011) .
Prostate biopsy was performed in a transrectal fashion using a commercially available TRUS system. Biopsy samples were taken at 8-10 cores guided by the same experienced physician in urological ultrasonography. One experienced urological pathologist reviewed the biopsy specimens.
Statistical analysis
Analysis was performed using the Statistical Package for Social Sciences software program (SPSS 19 for Windows). The total group were divided into PCa group and non-PCa group according to prostate biopsy result. Differences in continuous variables between groups were tested by the Mann-Whitney U tests. PSAV, PSAD and PSAVD were divided into quartiles, and we investigated the trends to determine which PSA derivatives were significant predictors for detecting PCa using univariate and multivariate logistic regression analysis. The diagnostic performance of these PSA-associated variables for detecting PCa was evaluated by a receiver operating characteristic (ROC) curve using MedCalc version 11.4.2. The area under the curves (AUC) of these indicators was compared by the chi-square test. Differences with a P-value less than 0.05 were considered significant.
Results
PCa was diagnosed in 44(22.8%) of the 193 men who had biopsies, characteristics of men with and without cancer are shown in Table 1 . There were significant differences between two groups in initial and last PV determined by TRUS, initial age , last serum PSA levels, PSAD, PSAV and PSAVD, whereas there was no significant difference in initial serum PSA level and follow-up period.
PSAV, PSAD and PSAVD were divided into quartiles (Table 2 ). Multivariate analysis was adjusted for initial age, initial serum PSA level, and initial PV for PSAV. For PSAVD and PSAD multivariate analysis was adjusted for initial age and initial serum PSA level. All of those indicators showed a positive trend for detecting PCa on univariate and multivariate analysis. ROC analysis (Figure 1 and Table 3) showed that PSAD and PSAVD were significantly better predictors of PCa than serum PSA. ROC analysis showed the cutoff of PSAVD was >0.023 ng·mL-1·y-1·cc-1, of which sensitivity, specificity, positive and negative predictive values was 73.7%, 70.7%, 45.2% and 89.1%, respectively. The diagnosis value of PSAVD was significantly higher than that of PSAV. However, the difference between PSAD and PSAVD was not significant. There was no statistical significant difference between the AUC of PSAV and that of last serum PSA level. Figure 2 and Table 4 show ROC analysis of participants with last serum PSA levels of 4.0ng/mL -10.0ng/mL. The diagnosis utility of PSAD and PSAVD was similar, and PSAVD performed significantly better than PSAV in PCa detection. Table 5 shows sensitivity, specificity, positive and negative predictive values of each variable, while maintaining 90% sensitivity, PSAVD (threshold>0.012 ng·mL-1·y-1·cc-1) enabled a one-half reduction in unnecessary biopsies.
Discussion
Widespread PSA-based screening has contributed to the improvement in PCa detection. In the United States, the incidence of PCa peaked in 1992 that was 5 years after the introduction of serum PSA test into PCa screening, since then the incidence has been decreasing slowly (Siegel et al., 2012) . However, the reference range for serum PSA level in normal men and PCa patients may overlap with each other. Consequently, several PSA-associated variables have been proposed in order to improve PCa detection, such as PSAV, PSAD and PSAVD.
PSAV is the rate of change in serum PSA level in a specified period. Carter et al. suggested that in men with a serum PSA level generally less than 4.0ng/mL, a PSAV above 0.35 ng·mL-1·y-1 may indicate clinically significant PCa when they are potentially curable (Carter et al., 2006) . It has been suggested by the same author that for men with indolent tumors or those men with BPH with a serum PSA level of greater than 4.0ng/mL to be identified, a cut point for PSAV less than 0.75ng·mL-1·y-1 should be recommended (Carter et al., 1992) .
Nevertheless, application of PSAV is limited by the necessity of using equipment and reagents from the same manufacturer (Smith et al., 1994) . Some studies do not confirm the usefulness of PSAV in diagnosing PCa in prescreened population. The study by Ulmert et al. (2008) suggested that, although PSAV had a strong association with a subsequent diagnosis of PCa, the predictive accuracy of PSA alone was not improved by adding PSAV. The Prostate Cancer Prevention Trial found that there was no increased value in predictive accuracy of detecting prostate cancer using PSAV (Thompson et al., 2006) . Schroder et al. (2006) suggested that PSAV does not improve the positive predictive value of a PSA cutoff of 4.0ng/mL in PCa screening. The European Randomized Study of Screening for Prostate Cancer suggested that using PSAV for predicting which men should undergo prostate biopsy would miss a large number of significant tumors with rising PSAV cut point ). In the present study there was no statistical significant difference between the AUC of PSAV and that of last serum PSA level.
PSAD has been shown to correlate with PCa presence, aggressiveness, pathologic tumor stage and progressionfree survival after treatment (Bretton et al., 1994; Allan et al., 2003) . Therefore, PSAD should be considered in PCa detection, especially those who have had prior TRUS measurements of PV (Zheng et al., 2008; Kawachi et al., 2010) . However, the optimal PSAD cutoff is still a controversy. Catalona et al. suggested that the commonly used PSAD cutoff of 0.15 detected only 59% of cancers (Catalona et al., 2000) .
Recently, Choi et al. (2011) put forward PSAVD as a new indicator in PCa detection and this proposal was mainly based on two reasons. First, they found a correlation between initial PV and prostate volume velocity (PVV) in the non-PCa group, which implied the larger prostate grew faster. Therefore they believed that initial PV could substitute for the PV change. Furthermore, Rhodes et al. (1999) reported a prostate growth rate of 1.6% per year among men residing in Olmsted County after 5 years of follow-up, which actually agrees with the first reason. The second reason was that TRUS is an uncomfortable and invasive procedure. Once patients take TRUS measurements of PV, the use of PSAVD will not require extra measurements before prostate biopsy, which is indeed much more convenient than the utility of PSAD. Compared with PSAV, PSAVD performed better in the diagnosis of PCa in the present study and the study carried out by Choi et al., although a previous TRUS measurement of PV is necessary in the application of PSAVD.
Several limitations of our study should be mentioned.
First, PV measurements in present study were carried out by TRUS, which has a disadvantage in that the results can vary depending on the individual sonographer performing the examination. The second limitation is that the data in present study was from only one hospital, which may introduce a selection bias and limit the general application of the conclusion. Therefore, subsequent studies with a greater number of individuals from various medical centers are necessary. In conclusions, in present study, PSAVD could be applied clinically to improve the diagnosis accuracy in PCa detection. PSAVD may be a better indicator of PCa than PSAV when previous PV measured by TRUS is available.
